Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.
Beini LyuYingying SangElizabeth SelvinAlex R ChangG Caleb AlexanderCheli Melzer CohenJosef CoreshVarda ShalevGabriel ChodickAvraham KarasikJuan-Jesus CarreroEdouard L FuYang XuMorgan E GramsJung-Im ShinPublished in: Diabetes care (2022)
There were substantial differences in real-world use of glucose-lowering medications across the U.S., Sweden, and Israel, with more optimal pharmacologic management in Israel. Variation in access to care and medication cost across countries may have contributed to these differences. SGLT2i and GLP1RA use in patients at high risk was limited in all three countries during this time period.
Keyphrases
- type diabetes
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- rheumatoid arthritis
- peritoneal dialysis
- prognostic factors
- quality improvement
- palliative care
- blood glucose
- adipose tissue
- combination therapy
- pain management
- chronic pain
- ankylosing spondylitis
- adverse drug
- health insurance